One of the most common categories of medications used today are blood pressure medications. A new breast cancer research study published in the journal Breast Cancer Research & Treatment explored the impact of two common types of blood pressure medications, beta blockers and ACE (angiotensin-converting enzyme) inhibitors, on breast cancer outcomes. The study investigators collected information from breast cancer patients who took part in the Life After Cancer Epidemiology (LACE) study regarding their use of these blood pressure medications and the incidence of breast cancer recurrence and mortality. The researchers reported:
Breast Cancer Recurrence...
- Use of ACE inhibitors increased the risk for breast cancer recurrence by about 56%
- Use of beta blockers modestly reduced the risk for breast cancer recurrence, but this was not statistically significant.
- The combined use of ACE inhibitors and beta blockers showed an intermediate risk for breast cancer recurrence, suggesting that beta blockers might suppress the negative impact of ACE inhibitors on breast cancer recurrence.
Overall & Breast Cancer-Specific Mortality...
- Neither ACE inhibitors nor beta blockers individually had any effect on breast cancer-specific mortality or overall mortality.
- Combined use of beta blockers and ACE inhibitors was linked with a 94% increased risk for all-cause mortality.
To learn about other diet and lifestyle choices to reduce your breast cancer risk, read my FREE book FIGHT NOW: EAT & LIVE PROACTIVELY AGAINST BREAST CANCER. Please recommend to anyone interested in breast cancer, breast cancer treatment, and breast cancer symptoms.